Immune-mediated rheumatic disorders are a group of systemic diseases associated with a relevant burden of morbidity and mortality worldwide.
Though not fully elucidated, the pathogenesis of these conditions seems to be the result of multiple modifiable and non-modifiable factors.
A genetic predisposition has been extensively described, and the detection of new susceptibility genes is of clinical relevance for the screening and individualized prevention of these diseases. Also, epigenetic modifications have been implicated in autoimmune responses, and miRNA targeting or increasing DNA methylation have been explored as potential treatments for these immunological diseases.
Notably, a link between epigenetic alternations and an impaired redox status has been suggested in these conditions. Namely, in rheumatic diseases, an overproduction of reactive oxygen species has been described, leading to DNA damage, lipid peroxidation, protein misfolding, and cell death. These oxidative mechanisms seem to concur with the disease pathogenesis as well as the increased risk of cardiovascular events associated with these diseases, and a potential role of redox-balancing approaches has been proposed.
Concomitantly, growing evidence indicates that a dysbiotic microbiome might be involved in the pathogenesis of immune-mediated conditions, although the precise mechanisms regulating this axis need to be clarified. In this context, targeting the microbiota via tailored microbiome-restoring interventions has been suggested as a promising approach to prevent or treat immune-mediated diseases.
Exploring the multifaceted pathogenesis of immune-mediates rheumatic diseases is pivotal to driving basic science into clinical practice, promoting personalized medicine, and tailoring prophylactic and therapeutic approaches.
This Research Topic aims to present recent advances and novel insights into the underlying mechanisms of immune-mediated rheumatic disorders, with a particular focus on the role of (epi)genetics, oxidative stress, and microbiome.
The final goal of this article collection is to help link bench to bedside research on the pathogenetic basis of immune-mediated rheumatic disorders, with the final aim of promoting novel tailored therapeutic approaches.
This Research Topic calls for Original Research, Review, Clinical Trial, and Perspective articles focusing on, but not limited to, the following subtopics related to pathogenetic mechanisms of immune-mediated rheumatic disorders:
• Genetic predisposition in immune-mediated rheumatic diseases
• The role of epigenetics in immune-mediated rheumatic diseases
• Oxidative stress in the pathogenesis of immune-mediated rheumatic diseases
• The role of redox-balancing interventions in immune-mediated rheumatic diseases
• The role of the microbiome in immune-mediated rheumatic diseases
• Tailored nutritional interventions to modulate the microbiota-immunity axis in immune-mediated rheumatic diseases
• Epigenetic and biochemical biomarkers for risk assessment and stratification in patients with immune-mediated rheumatic diseases
Immune-mediated rheumatic disorders are a group of systemic diseases associated with a relevant burden of morbidity and mortality worldwide.
Though not fully elucidated, the pathogenesis of these conditions seems to be the result of multiple modifiable and non-modifiable factors.
A genetic predisposition has been extensively described, and the detection of new susceptibility genes is of clinical relevance for the screening and individualized prevention of these diseases. Also, epigenetic modifications have been implicated in autoimmune responses, and miRNA targeting or increasing DNA methylation have been explored as potential treatments for these immunological diseases.
Notably, a link between epigenetic alternations and an impaired redox status has been suggested in these conditions. Namely, in rheumatic diseases, an overproduction of reactive oxygen species has been described, leading to DNA damage, lipid peroxidation, protein misfolding, and cell death. These oxidative mechanisms seem to concur with the disease pathogenesis as well as the increased risk of cardiovascular events associated with these diseases, and a potential role of redox-balancing approaches has been proposed.
Concomitantly, growing evidence indicates that a dysbiotic microbiome might be involved in the pathogenesis of immune-mediated conditions, although the precise mechanisms regulating this axis need to be clarified. In this context, targeting the microbiota via tailored microbiome-restoring interventions has been suggested as a promising approach to prevent or treat immune-mediated diseases.
Exploring the multifaceted pathogenesis of immune-mediates rheumatic diseases is pivotal to driving basic science into clinical practice, promoting personalized medicine, and tailoring prophylactic and therapeutic approaches.
This Research Topic aims to present recent advances and novel insights into the underlying mechanisms of immune-mediated rheumatic disorders, with a particular focus on the role of (epi)genetics, oxidative stress, and microbiome.
The final goal of this article collection is to help link bench to bedside research on the pathogenetic basis of immune-mediated rheumatic disorders, with the final aim of promoting novel tailored therapeutic approaches.
This Research Topic calls for Original Research, Review, Clinical Trial, and Perspective articles focusing on, but not limited to, the following subtopics related to pathogenetic mechanisms of immune-mediated rheumatic disorders:
• Genetic predisposition in immune-mediated rheumatic diseases
• The role of epigenetics in immune-mediated rheumatic diseases
• Oxidative stress in the pathogenesis of immune-mediated rheumatic diseases
• The role of redox-balancing interventions in immune-mediated rheumatic diseases
• The role of the microbiome in immune-mediated rheumatic diseases
• Tailored nutritional interventions to modulate the microbiota-immunity axis in immune-mediated rheumatic diseases
• Epigenetic and biochemical biomarkers for risk assessment and stratification in patients with immune-mediated rheumatic diseases
